Second autologous stem cell transplant for multiply relapsed Hodgkin's disease (Q44012472)

28 November 2017

title

Second autologous stem cell transplant for multiply relapsed Hodgkin's disease (English)

1 reference

28 November 2017

Lin TS

1

1 reference

28 November 2017

Avalos BR

2

1 reference

28 November 2017

Penza SL

3

1 reference

28 November 2017

Marcucci G

4

1 reference

28 November 2017

Elder PJ

5

1 reference

28 November 2017

Copelan EA

6

1 reference

28 November 2017

language of work or name

English

0 references

publication date

1 May 2002

1 reference

Bone Marrow Transplantation

28 November 2017

published in

1 reference

28 November 2017

volume

29

1 reference

28 November 2017

issue

9

1 reference

28 November 2017

page(s)

763-767

1 reference

The management of Hodgkin's disease: half a century of change. The Kaplan Memorial Lecture

28 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703546

High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: long-term follow-up in 128 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703546

Vinorelbine: an active drug for the management of patients with heavily pretreated Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703546

Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703546

Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. European Group for Blood and Bone Marrow Transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703546

The treatment of Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703546

7 January 2021

Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703546

7 January 2021

Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703546

7 January 2021

Role of a second transplant in the management of poor-prognosis lymphomas: a report from the European Blood and Bone Marrow Registry

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703546

7 January 2021

Mobilization of peripheral-blood progenitor cells with high-dose etoposide and granulocyte colony-stimulating factor in patients with breast cancer, non-Hodgkin's lymphoma, and Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703546

7 January 2021

Second transplants for leukaemic relapse after bone marrow transplantation: high early mortality but favourable effect of chronic GVHD on continued remission. A report by the EBMT Leukaemia Working Party

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703546

7 January 2021

Favorable prognosis after late relapse of Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703546

7 January 2021

Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703546

7 January 2021

Identifiers

DOI

10.1038/SJ.BMT.1703546

1 reference

28 November 2017

1 reference